close
close

23Andme Licensed Drug Developed Genetic Database Autoimmune Psoriasis Almirall

23Andme Licensed Drug Developed Genetic Database Autoimmune Psoriasis Almirall. 23andme licenses drug it developed to spanish drugmaker almirall 23andme has licensed an antibody it developed from its genetic database to treat inflammatory diseases to spanish drugmaker almirall sa.

My Biodata? I Don't Know Her The McGill Daily from www.mcgilldaily.com

The deal, announced by almirall in a filing with spanish regulators on thursday, marks the first time that 23andme has licensed a drug compound that it has developed itself, reports bloomberg. Last week, 23andme signed an agreement to allow the spanish pharmaceutical company almirall to further develop and commercialize the drug , which is designed to block certain small proteins associated with a variety of inflammatory. 23andme has licensed an antibody it developed from its genetic database to treat inflammatory diseases to spanish drugmaker almirall sa.

Last Week, 23Andme Signed An Agreement To Allow The Spanish Pharmaceutical Company Almirall To Further Develop And Commercialize The Drug , Which Is Designed To Block Certain Small Proteins Associated With A Variety Of Inflammatory.

Press j to jump to the feed. The drug the company sold to almirall is a molecule that blocks signals from small proteins that are involved in autoimmune diseases. This is the first time that the company has directly sold a product it created using the genetic information collected from users.

23Andme Has Licensed An Antibody It Developed From Its Genetic Database To Treat Inflammatory Diseases To Spanish Drugmaker Almirall Sa.

23andme has licensed an antibody it developed from its genetic database to treat inflammatory diseases to spanish drugmaker almirall sa. 85.8k members in the genealogy community. 23andme sells rights to drug it developed using customers' genetic information the drug is targeted to treat inflammatory diseases such as lupus, crohn's and psoriasis.

This Is The First Time 23Andme Is Licensing Its Own Drug Component And This Deal Was Announced By Almairall In A Filing With Spanish Regulators.

Known for its ancestry dna tests, the silicon valley firm 23andme inc. 23andme has licensed an antibody it developed from its genetic database to treat inflammatory diseases to spanish drugmaker almirall sa. 23andme has licensed an antibody it developed from its genetic database to treat inflammatory diseases to spanish drugmaker almirall sa.

The Drug Is Being Tested As A Treatment For Inflammatory Diseases Such As Lupus And Crohn’s Disease.

23andme licenses drug it developed to spanish drugmaker almirall Info picked up in regulatory finding. The company said that more than.

Bloomberg’s Kristen Brown Recently Reported Picked Up On The Deal Based.

Almirall will secure the rights to develop and commercialize the antibody for worldwide use. 23andme just gets deeper into drug development. The compound is a bispecific monoclonal antibody designed to block all 3.

Leave a Reply

Your email address will not be published.